Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

There was also a positive sign for investors worried about the rapid pace at which the company has been burning through its ...

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 ...

MRNA remains under pressure in 2025, despite recent next-gen COVID vaccine approval and upcoming cancer vaccine trial readouts. MRNA has a fully enrolled, 1089-patient study of mRNA-4157 in melanoma ...

Shares in Moderna and BioNTech have imploded since their 2021 peaks, shaving billions of dollars from their founders’ fortunes. Growing anti-vax hysteria and RFK Jr.’s FDA will likely make the ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2. The data ...

Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating COVID revenue, but it's insufficient to cover its operating expenses. It's ...